Self-reported diabetes is associated with allocentric spatial processing in the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study
- PMID: 36103146
- PMCID: PMC9828025
- DOI: 10.1111/ejn.15821
Self-reported diabetes is associated with allocentric spatial processing in the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study
Abstract
Type 2 diabetes is a robust predictor of cognitive impairment. Impairment in allocentric processing may help identify those at increased risk for Alzheimer's disease dementia. The objective of this study was to investigate the performance of participants with and without diabetes on a task of allocentric spatial processing. This was a cross-sectional secondary data analysis study using baseline data from the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS). Participants were aged 50 years and above and were free of dementia at baseline. Participants with no missing data on the variables of interest were included in this study. Our exposure variable was diabetes reported in the medical history. Our primary outcome was the Four Mountains Test (4MT), a novel task of allocentric processing. Covariates included demographics (age, sex, family history of dementia and years of education), APOEε4 carrier status, cognitive status (Clinical Dementia Rating scale), cerebrospinal fluid phosphorylated tau and amyloid-beta 1-42. Of 1324 participants (mean age = 65.95 (±7.45)), 90 had diabetes. Participants with diabetes scored 8.32 (±2.32) on the 4MT compared with 9.24 (±2.60) for participants without diabetes. In a univariate model, diabetes was significantly associated with worse 4MT total scores (β = -.92, p = .001), remaining significant in a fully adjusted model (β = -.64, p = .01). Cerebrospinal fluid phosphorylated tau was significantly higher in participants with diabetes compared with those without. Novel cognitive tests, such as the 4MT, may be appropriate to identify early cognitive changes in this high-risk group. Identifying those at greatest risk for future neurodegeneration is key to prevention efforts.
Keywords: Alzheimer's disease; cohort study; diabetes; prevention; risk factor.
© 2022 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
Conflict of interest statement
SG previously received salary from the EU/EFPIA grant that was used to fund the data collection (no. 115736) and holds a research grant from the Scottish Neurological Research Fund, which uses the Four Mountains Test as the primary outcome measure. KB has received consulting fees from Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics and Siemens Healthineers and is the co‐founder of Brain Biomarker Solutions (Gothenburg, Sweden). CWR has received consulting fees from Biogen, Eisai, MSD, Actinogen, Roche and Eli Lilly and speaker fees from Roche and Eisai. CWR sits on an NIHR data safety monitoring board and is on an advisory board for Roche Diagnostics. CWR is an unpaid chair of the Brain Health Clinic Consortium (sponsored by Biogen), unpaid chair of the Scottish Dementia Research Consortium and director of Brain Health Scotland. NZMH and GMT have no conflicts of interest to disclose.
Figures
Similar articles
-
Association between Longitudinal Cerebrospinal Fluid Alzheimer's Biomarkers and the Lifestyle for Brain Health (LIBRA) Index: Findings from the European Prevention of Alzheimer's Dementia Cohort Study (EPAD LCS).J Prev Alzheimers Dis. 2023;10(3):543-550. doi: 10.14283/jpad.2023.31. J Prev Alzheimers Dis. 2023. PMID: 37357296
-
Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers.J Alzheimers Dis. 2019;71(s1):S75-S83. doi: 10.3233/JAD-181265. J Alzheimers Dis. 2019. PMID: 31104024 Free PMC article.
-
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.JAMA Neurol. 2019 Jul 1;76(7):791-799. doi: 10.1001/jamaneurol.2019.0765. JAMA Neurol. 2019. PMID: 31009028 Free PMC article.
-
Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project.Lancet Psychiatry. 2016 Feb;3(2):179-86. doi: 10.1016/S2215-0366(15)00454-X. Epub 2015 Dec 10. Lancet Psychiatry. 2016. PMID: 26683239 Review.
-
Disease Modelling of Cognitive Outcomes and Biomarkers in the European Prevention of Alzheimer's Dementia Longitudinal Cohort.Front Big Data. 2021 Aug 20;4:676168. doi: 10.3389/fdata.2021.676168. eCollection 2021. Front Big Data. 2021. PMID: 34490422 Free PMC article. Review.
Cited by
-
The European Prevention of Alzheimer's Dementia Programme: An Innovative Medicines Initiative-funded partnership to facilitate secondary prevention of Alzheimer's disease dementia.Front Neurol. 2022 Nov 22;13:1051543. doi: 10.3389/fneur.2022.1051543. eCollection 2022. Front Neurol. 2022. PMID: 36484017 Free PMC article.
References
-
- Alzheimer's Disease International , Guerchet, M. , Prince, M. , & Prina, M. (2020). Numbers of people with dementia (Full Version, English).
-
- Bittner, T. , Zetterberg, H. , Teunissen, C. E. , Ostlund, R. E. Jr. , Militello, M. , Andreasson, U. , Hubeek, I. , Gibson, D. , Chu, D. C. , Eichenlaub, U. , Heiss, P. , Kobold, U. , Leinenbach, A. , Madin, K. , Manuilova, E. , Rabe, C. , & Blennow, K. (2016). Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid. Alzheimer's & Dementia, 12(5), 517–526. 10.1016/j.jalz.2015.09.009 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical